To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA)
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| An Expanded Clinical Study Evaluating the AAV2-RPE65 Gene Therapy(LX101) in Patients With LCA (NCT06024057) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2023-09-01 |
Track To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA) automatically
Every clearance here is in the API, with alerts when new ones post.